E-QURE CORP. (OTCMKTS:EQUR) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Effective July 25, 2018, E-Qure Corp. (the “Registrant”) announced the appointment of Mr. Ohad Goren, its Chief Executive Officer since June 2014, and Mr. Itsik Ben-Yesha, its Chief Technology Officer since June 2014, as members of the Registrant’s Board of Directors, joining Mr. Ron Weissberg and Dr. Michael Sessler on the Registrant’s Board.
Ohad Goren, age 49, Chief Executive Officer and Director. During the past five years, Mr. Goren has served in the following positions: from 2011 through 2013 Mr. Goren served as an advisor to several biotech and high-tech startup companies. During 2010 and 2011, Mr. Goren served as CEO of Pollogen Ltd., a private Israeli company engaged in the development, manufacture and marketing of medical aesthetic devices with sales in Europe, North and South America, and major Asian countries. Prior to joining Pollogen Ltd., during 2008 to 2009, Mr. Goren served as a consultant to startup companies principally in the biotechnology and hi-tech industries. From 2005 through 2008, Mr. Goren was the CEO of Lifewave Ltd., a public Israeli company, where he had responsibility for Lifewave’s IPO, overseeing the development of its chronic wound treatment device and Lifewave’s regulatory compliance, among other duties, and participated in the purchase by the Registrant of Lifewave’s patent for its chronic wound treatment device. From 1997 to 2005 Mr. Goren served as the Marketing and Sales Manager of the Services Division of Oracle Corp., in Israel. From 1990 to 1997 Mr. Goren served as the Deputy Consul at the Israeli Embassy, Washington, D.C. Mr. Goren received his BA degree from the University of Maryland, in the U.S.
Itsik Ben Yesha, age 67, Chief Technology Officer and Director: Mr. Ben-Yesha has served as the Registrant’s CTO since June 2014. From 1991 through 2013, Mr. Ben Yesha was the founder and a partner of Hisense Ltd., an Israeli medical device company for respiratory monitoring devices for infants. He previously served as Executive Vice President of Lifewave Ltd. From 1998 to 2003 Mr. Ben Yesha was the Executive Vice President and VPL Division President with Valor Computerized Systems Ltd., a CAD/CAM Software company listed on the Frankfurt Stock Exchange and later acquired by Mentor Graphics (NASDAQ: MENT). From 1979 to 1997, Mr. Ben Yesha served in Tadiran Telecom Group in various rolls, starting as a R&D engineer, designing computerized electronic exchanges (Tadex, Coral), and finally serving as the CFO of Tadiran Wireless Telecom division, bringing it from $0 to $50 million in annual sales within 3 years.
There are no family relationships between Messrs. Goren and Ben-Yesha and any of the Registrant’s other officers and directors. Other than as described in the 2017 Annual Report on Form 10-K filed with the SEC on April 17, 2018, there are no transactions to which the Registrant or any of its subsidiaries is a party in which Messrs. Goren and Ben-Yesha have had a material interest subject to disclosure under Item 404(a) of Regulation S-K.
About E-QURE CORP. (OTCMKTS:EQUR)
E-Qure Corp. owns intellectual property (IP) of technology of wound healing device. The IP assets, including the wound healing device, are designed for wound treatment incorporating Bioelectrical Signal Therapy (BST Device). The BST Device implements electrical stimulation technologies to treat hard-to-cure wounds and ulcers up to complete closure and/or cure. The BST Device, using electrodes affixed around the opposing sides of the wound, emits an electrical field around the wound and therefore mimics the electrochemical physiology principle and induces local cell regeneration. The BST Device is used to treat severe stage II, as well as stage III and IV wounds, including pressure ulcers, diabetic ulcers and venous ulcers. The BST Device is a device for adjunctive therapy in wound healing. The BST Device is able to automatically adjust the electric pulse amplitude based on a patient’s impedance reading.